CORONARY INTERVENT IONS

Aims: We sought to describe the differential effect of bleeding events in acute coronary syndromes (ACS) on shortand long-term mortality according to their type and severity. Methods and results: The PLATO trial randomised 18,624 ACS patients to clopidogrel or ticagrelor. Postrandomisation bleeding events were captured according to bleeding type (spontaneous or procedure-related), with PLATO, TIMI, and GUSTO definitions. The association of bleeding events with subsequent short-term (<30 days) and long-term (>30 days) all-cause mortality was assessed using time-dependent Cox proportional hazard models. A model was fitted to compare major and minor bleeding for mortality prediction. Of 18,624 patients, 2,189 (11.8%) had at least one PLATO major bleed (mean follow-up 272.2±123.5 days). Major bleeding was associated with higher short-term mortality (adjusted hazard ratio [HR] 9.28; 95% confidence interval [CI]: 7.50-11.48) but not with long-term mortality (adjusted HR 1.28; 95% CI: 0.93-1.75). Spontaneous bleeding was associated with short-term (adjusted HR 14.59; 95% CI: 11.14-19.11) and longterm (adjusted HR 3.38; 95% CI: 2.26-5.05) mortality. Procedure-related bleeding was associated with shortterm mortality (adjusted HR 5.29; 95% CI: 4.06-6.87): CABG-related and non-coronary-procedure-related bleeding were associated with a higher short-term mortality, whereas PCI or angiography-related bleeding was not associated with either shortor long-term mortality. Similar results were obtained using the GUSTO and TIMI bleeding definitions. Conclusions: Major bleeding is associated with high subsequent mortality in ACS. However, this association is much stronger in the first 30 days and is strongest for spontaneous (vs. procedure-related) bleeding. KEYWORDS

[1]  G. Niccoli,et al.  The combined use of Drug-eluting balloon and Excimer laser for coronary artery Restenosis In-Stent Treatment: The DERIST study. , 2017, Cardiovascular revascularization medicine : including molecular interventions.

[2]  M. Isobe,et al.  The effectiveness of excimer laser coronary atherectomy with contrast medium for underexpanded stent: The findings of optical frequency domain imaging , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[3]  Francesco Versaci,et al.  Clinical Impact of OCT Findings During PCI: The CLI-OPCI II Study. , 2015, JACC. Cardiovascular imaging.

[4]  J. Moses,et al.  Excimer Laser Angioplasty-Facilitated Fracturing of Napkin-Ring Peri-Stent Calcium in a Chronically Underexpanded Stent: Documentation by Optical Coherence Tomography. , 2015, JACC. Cardiovascular interventions.

[5]  Gary S Mintz,et al.  Intravascular imaging of coronary calcification and its clinical implications. , 2015, JACC. Cardiovascular imaging.

[6]  R. Peters,et al.  Prognostic value of access site and nonaccess site bleeding after percutaneous coronary intervention: a cohort study in ST-segment elevation myocardial infarction and comprehensive meta-analysis. , 2014, JACC. Cardiovascular interventions.

[7]  G. Niccoli,et al.  Excimer Laser LEsion modification to expand non-dilatable stents: the ELLEMENT registry. , 2014, Cardiovascular revascularization medicine : including molecular interventions.

[8]  A. Kastrati,et al.  Weight of the bleeding impact on early and late mortality after percutaneous coronary intervention , 2014, Journal of Thrombosis and Thrombolysis.

[9]  M. Marjanović,et al.  Prognostic implications of bleeding measured by Bleeding Academic Research Consortium (BARC) categorisation in patients undergoing primary percutaneous coronary intervention , 2013, Heart.

[10]  A. Kastrati,et al.  Prognostic Value of Access and Non–Access Sites Bleeding After Percutaneous Coronary Intervention , 2013, Circulation. Cardiovascular interventions.

[11]  Sunil V. Rao,et al.  The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction. , 2012, European heart journal.

[12]  M. Egred A novel approach for under-expanded stent: excimer laser in contrast medium. , 2012, The Journal of invasive cardiology.

[13]  Peter K. Smith,et al.  Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. , 2012, Journal of the American College of Cardiology.

[14]  M. Hadamitzky,et al.  Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention , 2012, Circulation.

[15]  Deepak L. Bhatt,et al.  Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. , 2011, American heart journal.

[16]  E. Antman,et al.  Predictors of Bleeding and Time Dependence of Association of Bleeding With Mortality: Insights From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel—Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) , 2011, Circulation.

[17]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[18]  S. Pocock,et al.  Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI , 2011, JACC. Cardiovascular interventions.

[19]  Sunil V. Rao,et al.  Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. , 2011, JACC. Cardiovascular interventions.

[20]  E. Antman,et al.  Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. , 2010, European heart journal.

[21]  S. Steinhubl,et al.  Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial. , 2010, American heart journal.

[22]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[23]  A. Skene,et al.  Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. , 2009, American heart journal.

[24]  L. Bilodeau,et al.  High energy excimer laser to treat coronary in‐stent restenosis in an underexpanded stent , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[25]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[26]  S. Yusuf,et al.  Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.

[27]  Robert M Califf,et al.  A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. , 2006, Journal of the American College of Cardiology.

[28]  R. Califf,et al.  Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. , 2005, The American journal of cardiology.

[29]  R. Giugliano,et al.  Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes , 2005, Circulation.

[30]  Marc Cohen Predictors of bleeding risk and long-term mortality in patients with acute coronary syndromes , 2005, Current medical research and opinion.

[31]  W Klein,et al.  Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). , 2004, European heart journal.

[32]  Ramires,et al.  Patient-Related and Angiographic Predictors of Restenosis After Excimer Laser Coronary Angioplasty. , 1998, The Journal of invasive cardiology.

[33]  M. Leon,et al.  Treatment of in-stent restenosis with excimer laser coronary angioplasty: mechanisms and results compared with PTCA alone. , 1997, Circulation.

[34]  F. Schwarz,et al.  Randomized comparison of angioplasty of complex coronary lesions at a single center. Excimer Laser, Rotational Atherectomy, and Balloon Angioplasty Comparison (ERBAC) Study. , 1997, Circulation.

[35]  J. Tijssen,et al.  Randomised trial of excimer laser angioplasty versus balloon angioplasty for treatment of obstructive coronary artery disease , 1996, The Lancet.

[36]  L. Deckelbaum,et al.  Development of a new technique for reducing pressure pulse generation during 308-nm excimer laser coronary angioplasty. , 1995, Catheterization and cardiovascular diagnosis.

[37]  Frank Litvack,et al.  PERCUTANEOUS EXCIMER LASER CORONARY ANGIOPLASTY , 1989, The Lancet.